Enliven Therapeutics
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies for precision oncology applications. The company utilizes a chemistry-driven platform to engineer targeted therapies designed to overcome resistance mechanisms in cancer patients. Its lead clinical development pipeline includes ELVN-001, a selective tyrosine kinase inhibitor for chronic myeloid leukemia, and ELVN-002, a HER2-selective inhibitor targeting solid tumors. Core operations encompass pre-clinical targeted drug discovery, medicinal chemistry, clinical trial management, and biomarker discovery. As a clinical-stage development firm, the company currently generates limited commercial revenue, funding operations through equity capital, collaborations, and partnership agreements. Enliven occupies an emerging position in precision oncology innovation. The company is headquartered in Boulder, Colorado, United States, and its common stock trades on the Nasdaq Global Market.
7 of the funds FundTelligence covers report a position in Enliven Therapeutics.
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 7
- Exposure themes
- Precision Medicine & Genomics, Precision Oncology, Precision Therapeutics
Funds holding Enliven Therapeutics
- Polar Capital Healthcare Opportunities Fund — Polar Capital · 6.5 % (largest positions only, October 2026)
- Polar Capital Healthcare Discovery Fund — Polar Capital · 2.6 % (largest positions only, October 2026)
- DNB Bioteknologi — DNB · 1.02 % (full portfolio disclosed, September 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.23 % (full portfolio disclosed, October 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.03 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.02 % (partially disclosed portfolio, June 2026)
- DNB Global Enhanced Small Cap — DNB · 0.02 % (full portfolio disclosed, September 2026)